Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. SPY
6. LMT
7. WMT
8. CMPS
9. NVDA
10. RXST

Go back to Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) Delayed: 26.20 +0.43 (1.67%)
Previous Close $25.77    52 Week High $42.49 
Open $26.15    52 Week Low $16.64 
Day High $26.35    P/E N/A 
Day Low $25.63    EPS $-0.42 
Volume 1,674,460       

NEWMARKET CORPORATION (NYSE: NEU) Delayed: 795.68 -1.15 (0.14%)
Previous Close $796.83    52 Week High $447.97 
Open $801.66    52 Week Low $322.54 
Day High $803.24    P/E 43.69 
Day Low $786.49    EPS $18.21 
Volume 76,900